Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Assets: 2011-2025

Historic Non-Current Assets for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $25.5 million.

  • Capricor Therapeutics' Non-Current Assets rose 257.54% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 257.54%. This contributed to the annual value of $7.1 million for FY2024, which is 9.94% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Non-Current Assets of $25.5 million as of Q3 2025, which was up 169.91% from $9.4 million recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Non-Current Assets high stood at $25.5 million for Q3 2025, and its period low was $928,489 during Q1 2021.
  • Over the past 3 years, Capricor Therapeutics' median Non-Current Assets value was $7.6 million (recorded in 2024), while the average stood at $9.3 million.
  • As far as peak fluctuations go, Capricor Therapeutics' Non-Current Assets surged by 469.50% in 2022, and later declined by 9.94% in 2024.
  • Capricor Therapeutics' Non-Current Assets (Quarterly) stood at $4.9 million in 2021, then skyrocketed by 47.26% to $7.2 million in 2022, then rose by 9.33% to $7.9 million in 2023, then decreased by 9.94% to $7.1 million in 2024, then soared by 257.54% to $25.5 million in 2025.
  • Its last three reported values are $25.5 million in Q3 2025, $9.4 million for Q2 2025, and $7.5 million during Q1 2025.